Immunomedics, Inc. Announces Results From 3 Clinical Trials Will be Presented at the 59th Annual Meeting of the Society of Nuclear Medicine

MORRIS PLAINS, N.J., June 5, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 7 presentations, of which 6 are oral presentations, will be given at the 59th Annual Meeting of the Society of Nuclear Medicine (SNM), scheduled for June 9 – 13, 2012, in Miami Beach, FL.